JP2010529026A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529026A5
JP2010529026A5 JP2010510385A JP2010510385A JP2010529026A5 JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5 JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010510385 A JP2010510385 A JP 2010510385A JP 2010529026 A5 JP2010529026 A5 JP 2010529026A5
Authority
JP
Japan
Prior art keywords
composition
booster
human
peptide
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010510385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529026A (ja
JP5635399B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/060044 external-priority patent/WO2008150577A1/en
Publication of JP2010529026A publication Critical patent/JP2010529026A/ja
Publication of JP2010529026A5 publication Critical patent/JP2010529026A5/ja
Application granted granted Critical
Publication of JP5635399B2 publication Critical patent/JP5635399B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010510385A 2007-06-01 2008-04-11 乳癌再発の予防のためのワクチン Expired - Fee Related JP5635399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94152407P 2007-06-01 2007-06-01
US60/941,524 2007-06-01
PCT/US2008/060044 WO2008150577A1 (en) 2007-06-01 2008-04-11 Vaccine for the prevention of breast cancer relapse

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014138567A Division JP6097724B2 (ja) 2007-06-01 2014-07-04 乳癌再発の予防のためのワクチン

Publications (3)

Publication Number Publication Date
JP2010529026A JP2010529026A (ja) 2010-08-26
JP2010529026A5 true JP2010529026A5 (enExample) 2011-04-28
JP5635399B2 JP5635399B2 (ja) 2014-12-03

Family

ID=40094045

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2010510385A Expired - Fee Related JP5635399B2 (ja) 2007-06-01 2008-04-11 乳癌再発の予防のためのワクチン
JP2014138567A Expired - Fee Related JP6097724B2 (ja) 2007-06-01 2014-07-04 乳癌再発の予防のためのワクチン
JP2016211150A Pending JP2017071607A (ja) 2007-06-01 2016-10-28 乳癌再発の予防のためのワクチン
JP2018153050A Expired - Fee Related JP7072467B2 (ja) 2007-06-01 2018-08-16 乳癌再発の予防のためのワクチン
JP2020161232A Pending JP2021001218A (ja) 2007-06-01 2020-09-25 乳癌再発の予防のためのワクチン
JP2022068170A Pending JP2022095926A (ja) 2007-06-01 2022-04-18 乳癌再発の予防のためのワクチン

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2014138567A Expired - Fee Related JP6097724B2 (ja) 2007-06-01 2014-07-04 乳癌再発の予防のためのワクチン
JP2016211150A Pending JP2017071607A (ja) 2007-06-01 2016-10-28 乳癌再発の予防のためのワクチン
JP2018153050A Expired - Fee Related JP7072467B2 (ja) 2007-06-01 2018-08-16 乳癌再発の予防のためのワクチン
JP2020161232A Pending JP2021001218A (ja) 2007-06-01 2020-09-25 乳癌再発の予防のためのワクチン
JP2022068170A Pending JP2022095926A (ja) 2007-06-01 2022-04-18 乳癌再発の予防のためのワクチン

Country Status (16)

Country Link
US (6) US8222214B2 (enExample)
EP (2) EP2722336A1 (enExample)
JP (6) JP5635399B2 (enExample)
KR (5) KR101572474B1 (enExample)
CN (2) CN105816867A (enExample)
AU (1) AU2008260399C1 (enExample)
CA (1) CA2687368C (enExample)
CY (1) CY1114912T1 (enExample)
DK (1) DK2162149T3 (enExample)
ES (1) ES2445399T3 (enExample)
HR (1) HRP20140102T1 (enExample)
MX (1) MX2009012858A (enExample)
PL (1) PL2162149T3 (enExample)
PT (1) PT2162149E (enExample)
SI (1) SI2162149T1 (enExample)
WO (1) WO2008150577A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
HRP20140102T1 (hr) * 2007-06-01 2014-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cjepivo za prevenciju relapsa raka dojke
KR20170097234A (ko) 2008-12-10 2017-08-25 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 유방암 재발 예방용 백신
CN104271591B (zh) 2012-02-17 2017-09-26 梅约医学教育与研究基金会 用于生成能够识别表达HER2/neu多肽的癌细胞的CD8+T细胞的方法和材料
WO2013169538A1 (en) 2012-05-08 2013-11-14 Albert Einstein College Of Medicine Of Yeshiva University Nanoparticle delivery vehicle for s-nitroso-n-acetyl cysteine and uses thereof
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
CA2840997A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
CN103961700A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
EP2777711A1 (en) 2013-03-11 2014-09-17 Icon Genetics GmbH Her2/Neu cancer vaccine
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015066020A1 (en) * 2013-10-28 2015-05-07 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of monitoring immune responses
US10434152B2 (en) * 2014-02-20 2019-10-08 Wayne State University HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas
WO2017132562A1 (en) 2016-01-29 2017-08-03 Heyue Zhou Antigen binding proteins that bind pd-l1
EP3463438B1 (en) 2016-05-31 2022-04-06 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine therapy for treatment of endometrial and ovarian cancer
US11564987B2 (en) 2018-10-21 2023-01-31 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
US20240183856A1 (en) 2021-05-04 2024-06-06 Aston Sci. Inc. Her2 vaccine composition
KR20230017640A (ko) 2021-07-28 2023-02-06 주식회사 애스톤사이언스 Her2 백신 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
DE69031120T2 (de) * 1989-05-19 1998-01-15 Genentech, Inc., South San Francisco, Calif. Her2 extrazellulare domäne
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US20030022820A1 (en) * 1995-12-14 2003-01-30 Linda A. Sherman In vivo activation of tumor-specific cytotoxic t cells
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1246597B1 (en) * 1999-08-03 2015-01-14 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
AU7743100A (en) 1999-09-30 2001-04-30 Corixa Corporation Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
US6602510B1 (en) * 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20030224036A1 (en) * 1999-12-13 2003-12-04 Fikes John D Hla class I a2 tumor associated antigen peptides and vaccine compositions
US20070098776A1 (en) * 1999-12-13 2007-05-03 Fikes John D HLA class I A2 tumor associated antigen peptides and vaccine compositions
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
WO2003004609A2 (en) * 2001-07-03 2003-01-16 Lexicon Genetics Incorporated Novel human kielin-like proteins and polynucleotides encoding the same
WO2003005952A2 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US8802618B2 (en) 2002-03-08 2014-08-12 Board Of Regents, The University Of Texas System Controlled modulation of amino acid side chain length of peptide antigens
KR100555211B1 (ko) * 2002-07-16 2006-03-03 주식회사 팬제노믹스 항암효과를 갖는 Ｈｅｒ-２/ｎｅｕ ＤＮＡ 백신
EP1553966B1 (en) * 2002-10-03 2012-08-01 Wyeth Holdings Corporation Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
WO2004069866A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
WO2005046571A2 (en) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005014634A1 (en) 2003-08-12 2005-02-17 Agt Biosciences Limited A gene and uses therefor
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
US20060275777A1 (en) * 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
HRP20140102T1 (hr) * 2007-06-01 2014-03-28 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cjepivo za prevenciju relapsa raka dojke

Similar Documents

Publication Publication Date Title
JP2010529026A5 (enExample)
HRP20140102T1 (hr) Cjepivo za prevenciju relapsa raka dojke
Wallach et al. Advances in the treatment of neuromyelitis optica spectrum disorder
CN107519486B (zh) 于感染性与恶性疾病的治疗中提升免疫反应的方法
RU2435782C2 (ru) Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
JP2014114288A5 (enExample)
Melo et al. Golimumab (anti-TNF monoclonal antibody): where we stand today
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2016530323A5 (enExample)
JP2015508774A5 (enExample)
JP2012102122A5 (enExample)
WO2017177207A1 (en) Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
CN108392633A (zh) Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用
US9884098B2 (en) Multivalent breast cancer vaccine
JP2024001125A (ja) Ｉｌ－１７アンタゴニストを用いて初発プラーク型乾癬を治療する方法
JP2015517511A5 (enExample)
JP2014500278A5 (enExample)
JP2015526446A5 (enExample)
AU2025202861A1 (en) Vaccine compositions and methods for restoring NKG2D pathway function against cancers
JP2014500278A (ja) 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与
JP2021514003A5 (enExample)
CN106540256A (zh) 环二核苷酸-脂质体偶联单克隆抗体在抗肿瘤中的应用
JP2018522041A (ja) 改変酵母−ブラキュリー免疫療法組成物
JP2015172060A5 (enExample)
JP2023536655A5 (enExample)